Keep Head & Neck Cancer Away®

Two different diseases, one label

This distinction is the single most useful thing on this page, and it is routinely missed.

HPV-positive oropharyngeal cancer arises at the back of the throat — tonsil and base of tongue. It is caused by human papillomavirus, typically acquired decades earlier. It tends to occur in people in their 40s to 60s, often non-smokers, and frequently presents as a painless lump in the neck rather than a sore throat. It responds to treatment markedly better, and it is staged on a completely separate scale precisely because the old staging overstated risk for these patients.

HPV-negative head and neck cancer is the traditional disease — driven by tobacco and alcohol, arising anywhere in the mouth, throat or voice box, more often in older patients, and harder to cure at the same anatomical stage.

If you have been given a stage number, ask which staging system was used and whether your tumour is p16/HPV positive. A patient with HPV-positive stage I disease and one with HPV-negative stage I disease are in very different situations, and survival figures found online rarely separate them.

Who is at risk

• HPV infection — now the leading cause of oropharyngeal cancer in the United States, and the reason overall rates are rising. HPV vaccination prevents the infections that cause it; it is recommended for boys as well as girls.
• Tobacco in every form — cigarettes, cigars, pipes, chewing tobacco, snuff, and betel quid.
• Heavy alcohol — and alcohol combined with tobacco multiplies risk rather than simply adding to it.
• Sun exposure for lip cancer.
• Epstein-Barr virus for nasopharyngeal cancer, which is far more common in parts of Asia and North Africa.
• Occupational exposures — wood dust, nickel, formaldehyde (nasal and sinus cancers).
• Poor oral health, previous head and neck cancer, and a suppressed immune system.
• Some people have none of these. HPV-positive cancer commonly occurs in people who never smoked and drink little.

Finding it early

There is no population screening programme, but the mouth and throat are among the few places a clinician can actually look. Your dentist examines this area at every check-up — dentists find a meaningful share of oral cancers, which is a good reason to keep going.

Symptoms that should be evaluated if they persist beyond about three weeks:

• A lump in the neck that does not go away — the most common first sign of HPV-positive cancer, and usually painless.
• A mouth ulcer or sore that will not heal, or a red or white patch that persists.
• Hoarseness lasting more than three weeks — the classic warning for voice box cancer, and a symptom that gets attributed to a cold for months.
• Difficulty or pain on swallowing, a persistent sore throat, or the sensation of something stuck.
• Persistent ear pain with a normal ear examination — referred pain from the throat, and an easily missed clue.
• Unexplained loose teeth, numbness of the lip or tongue, a nose blocked on one side, or persistent nosebleeds.

Only about a quarter of these cancers are found while still localized, and more than half are already in the lymph nodes at diagnosis. A neck lump in an adult is not a wait-and-see problem.

How it’s diagnosed

Assessment involves examination with a flexible scope passed through the nose to see the throat and voice box — uncomfortable for a few seconds, not painful — plus imaging (CT, MRI, often PET/CT) and a biopsy.

For a neck lump, the first test is usually a fine needle aspiration. An open surgical biopsy of a neck node should generally be avoided before a primary tumour has been looked for, because it can complicate later treatment. If someone proposes simply cutting out the lump, it is reasonable to ask whether the throat has been examined first.

p16 immunohistochemistry (a marker for HPV) is essential on any oropharyngeal tumour. It determines the staging system, influences treatment intensity, and is the main determinant of prognosis. Ask for the result.

Because treatment affects eating, speaking and teeth, good centres involve a dentist, speech and swallowing therapist and dietitian before treatment begins — not after problems appear.

Staging explained simply

Two things make head and neck staging unusual. First, HPV-positive oropharyngeal cancer uses its own staging system, because the same anatomical extent carries a much better outlook — a patient who would once have been called stage IV may now be stage I. Second, stage IV here does not mean incurable; it often reflects lymph node involvement in the neck rather than distant spread, and cure remains the goal.

Grading and biology

Most head and neck cancers are squamous cell carcinomas, graded 1–3 by how abnormal the cells look. Grade matters far less here than HPV status.

p16/HPV positivity is the dominant biological factor. HPV-positive tumours are more sensitive to radiation and chemotherapy, and outcomes are substantially better stage for stage. Smoking history modifies this — an HPV-positive cancer in a heavy long-term smoker does not do quite as well as one in a never-smoker, which is one more reason stopping smoking at diagnosis is worth doing.

Other findings that shape treatment: extranodal extension (cancer growing through the capsule of a lymph node), positive surgical margins, and perineural or lymphovascular invasion. These are the features that usually trigger radiation or chemoradiation after surgery.

How it’s treated

Radiation is a primary curative treatment for head and neck cancer — not an add-on. For many tumours of the throat and voice box, radiation (with chemotherapy for larger tumours) cures at rates comparable to surgery while preserving the ability to speak and swallow. That trade-off is the central decision in this disease.

Surgery is preferred for many oral cavity cancers and for selected throat tumours, increasingly using minimally invasive transoral robotic techniques. Reconstruction may be needed.

Chemoradiation — radiation with cisplatin — is standard for locally advanced disease, and after surgery when high-risk features are found.

Technique matters more here than almost anywhere. Intensity-modulated radiation therapy (IMRT) shapes dose away from the salivary glands, reducing permanent dry mouth. Careful sparing of the swallowing muscles reduces long-term swallowing problems. Proton therapy is used in selected cases. If you are being treated for head and neck cancer, it is entirely reasonable to ask how your plan protects your salivary glands and swallowing muscles.

Immunotherapy is used in recurrent and metastatic disease.

Where CureRays fits: this is the heart of radiation oncology, and it is Dr. Hess's own subspecialty background — he treated head and neck cancers with photon and proton therapy at Emory. If you want a radiation opinion on a head and neck cancer, this is the right place to ask.

What the guidelines say

In broad strokes: test every oropharyngeal tumour for p16/HPV and stage it on the appropriate system; treat early-stage disease with single-modality surgery or radiation; treat locally advanced disease with chemoradiation or surgery followed by risk-adapted radiation with or without chemotherapy; involve dental, speech-swallowing and nutrition services before treatment starts; and use immunotherapy for recurrent or metastatic disease. De-escalation of treatment for HPV-positive cancer is an active research area — ask about clinical trials.

Your team will follow national guidelines such as those from the National Comprehensive Cancer Network (NCCN). The above is a plain-language overview of the general approach, not the guideline itself. NCCN publishes free NCCN Guidelines for Patients®.

Outcomes and odds of cure

Source: NCI SEER Cancer Stat Facts: Oral Cavity and Pharynx Cancer, SEER 21 (excluding IL), 2016–2022. In 2026 an estimated 60,480 people will be diagnosed and about 13,150 will die of it.

These are population statistics from the National Cancer Institute's SEER program. They describe large groups of people, not any one person, and lag current treatment by several years. They cannot predict what will happen to you.

These combined figures understate HPV-positive disease and overstate HPV-negative disease, because SEER reports them together. People with HPV-positive oropharyngeal cancer generally do considerably better than the table suggests. Ask your team for figures matched to your HPV status, stage and smoking history.

The trend is unusual and worth naming: new cases have been rising about 1.0% a year and deaths rising about 0.8% a year (SEER, through 2024) — driven by HPV-related disease. Overall 5-year survival has nonetheless improved markedly since the 1970s, from around 54% to about 75%.

Side effects and how we watch for them

Head and neck radiation asks a lot of patients, and being told the truth in advance helps more than reassurance.

During treatment: sore mouth and throat (mucositis) that peaks in the later weeks, thick saliva then dryness, altered or lost taste, skin reaction over the neck, fatigue, and difficulty eating. Weight loss is the main practical risk — a dietitian should be involved from the start, and a feeding tube is sometimes planned in advance rather than treated as a failure.

Long term: dry mouth (much reduced by IMRT but often not eliminated), dental decay, swallowing difficulty, stiffness of the jaw or neck, thyroid underactivity — thyroid function should be checked yearly for life if your neck was irradiated, and this is commonly forgotten. Lymphoedema of the face and neck is also common and treatable.

See a dentist before treatment starts. Teeth that need attention should be dealt with beforehand, because extractions after radiation carry a risk of jaw bone injury.

Swallowing exercises during treatment genuinely preserve function — do them even when swallowing hurts and eating feels pointless. This is the single most valuable thing you can do for yourself during the six weeks.

How it is assessed: graded at each visit on a standard scale, with weight, swallowing and mouth care reviewed weekly during treatment.

Follow-up, remission and survivorship

Remission means no detectable cancer. A PET/CT is usually done around three months after chemoradiation to confirm response; scans done too early can be misleading.

Follow-up is examination every 1–3 months in the first year, stretching out over five years, because most recurrences appear early. Continued surveillance matters because second cancers of the head, neck, oesophagus and lung are a real risk, particularly in smokers.

Survivorship is where head and neck cancer differs most from other cancers, because the effects are visible and social: speech, swallowing, taste, appearance, dry mouth, dental care, and the isolation that comes from struggling to eat with other people. Speech and swallowing therapy, dental follow-up, thyroid monitoring and psychological support should be part of the plan rather than optional extras.

Stopping smoking and drinking after diagnosis measurably improves outcomes and reduces second cancers. It is the hardest thing to hear at the worst possible moment, and it is true.

Questions people actually ask

Informational only, not medical advice — confirm with your care team.

Go deeper on head and neck cancer

Read the full plain-language guide, or ask our radiation team about salivary and swallowing sparing in your plan.

Full head & neck cancer guide

Watch: xerostomia (dry mouth)

Dry mouth is one of the most common lasting effects of radiation to the head and neck. This walks through why it happens, what helps, and when to tell your team.